Literature DB >> 8990278

Inhibition of monoamine oxidase A by beta-carboline derivatives.

H Kim1, S O Sablin, R R Ramsay.   

Abstract

beta-Carbolines are endogenous inhibitors of monoamine oxidase (MAO). The interaction of nine beta-carboline derivatives and four 3,4-dihydro forms with purified MAO A was investigated. All the compounds tested were reversible competitive inhibitors selective for MAO A, in agreement with previous studies on membrane preparations. The oxidation of kynuramine by MAO A in the presence of the more effective inhibitors showed a lag period before reaching the steady state. In general, the 1-methyl and 7-methoxy substituents increased the potency. Harmine, 2-methylharminium, 2,9-dimethylharminium, and harmaline were the most effective inhibitors of the purified MAO A, with low Ki values of 5, 69, 15, and 48 nM, respectively. The inhibitors interacted with the covalently bound flavin to induce distinct spectral changes, the magnitude of which correlated with the efficacy of the inhibition. The more effective inhibitors could be in situ inhibitors of MAO A.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8990278     DOI: 10.1006/abbi.1996.9771

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  43 in total

1.  Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).

Authors:  Tatyana Adayev; Jerzy Wegiel; Yu-Wen Hwang
Journal:  Arch Biochem Biophys       Date:  2010-12-24       Impact factor: 4.013

2.  Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression.

Authors:  Yun Li; Rita Sattler; Eun Ju Yang; Alice Nunes; Yoko Ayukawa; Sadia Akhtar; Grace Ji; Ping-Wu Zhang; Jeffrey D Rothstein
Journal:  Neuropharmacology       Date:  2010-10-27       Impact factor: 5.250

3.  Potentiation of 5-methoxy-N,N-dimethyltryptamine-induced hyperthermia by harmaline and the involvement of activation of 5-HT1A and 5-HT2A receptors.

Authors:  Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Neuropharmacology       Date:  2015-02       Impact factor: 5.250

4.  Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Authors:  Benjamin J Malcolm; Kelly C Lee
Journal:  Ment Health Clin       Date:  2018-03-23

5.  [11C]Harmine Binding to Brain Monoamine Oxidase A: Test-Retest Properties and Noninvasive Quantification.

Authors:  Francesca Zanderigo; Alexandra E D'Agostino; Nandita Joshi; Martin Schain; Dileep Kumar; Ramin V Parsey; Christine DeLorenzo; J John Mann
Journal:  Mol Imaging Biol       Date:  2018-08       Impact factor: 3.488

6.  Potent inhibition of human organic cation transporter 2 (hOCT2) by β-carboline alkaloids.

Authors:  David J Wagner; Haichuan Duan; Alenka Chapron; Richard W Lee; Joanne Wang
Journal:  Xenobiotica       Date:  2017-03-02       Impact factor: 1.908

Review 7.  Kinetics, mechanism, and inhibition of monoamine oxidase.

Authors:  Rona R Ramsay; Alen Albreht
Journal:  J Neural Transm (Vienna)       Date:  2018-03-07       Impact factor: 3.575

8.  Chronic administration of harmine elicits antidepressant-like effects and increases BDNF levels in rat hippocampus.

Authors:  Jucélia J Fortunato; Gislaine Z Réus; Tamires R Kirsch; Roberto B Stringari; Gabriel R Fries; Flávio Kapczinski; Jaime E Hallak; Antônio W Zuardi; José A Crippa; João Quevedo
Journal:  J Neural Transm (Vienna)       Date:  2010-08-05       Impact factor: 3.575

9.  Behavioral and pharmacokinetic interactions between monoamine oxidase inhibitors and the hallucinogen 5-methoxy-N,N-dimethyltryptamine.

Authors:  Adam L Halberstadt
Journal:  Pharmacol Biochem Behav       Date:  2016-01-15       Impact factor: 3.533

10.  In vivo comparison of harmine efficacy against psychostimulants: preferential inhibition of the cocaine response through a glutamatergic mechanism.

Authors:  Suzan Owaisat; Robert B Raffa; Scott M Rawls
Journal:  Neurosci Lett       Date:  2012-08-03       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.